Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer

Launched by JENA UNIVERSITY HOSPITAL · Apr 6, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to treating early-stage prostate cancer using a special type of radiation therapy called ultrahypofractionated radiotherapy. This method delivers higher doses of radiation in fewer sessions, which may help improve patients' quality of life during treatment. The trial will use a cutting-edge device that adjusts the radiation treatment each day based on changes in a patient’s anatomy. Researchers will gather information about how patients feel during and after treatment through a digital questionnaire, comparing their experiences to those of patients who received traditional radiation therapy.

To participate in this trial, men aged between 65 and 74 who have not received certain hormone treatments in the last two months and are in good health may be eligible. Participants can expect to have their radiation therapy adjusted daily for the best possible results while providing feedback on their experience. It's important to note that this trial is not yet recruiting participants, but it aims to understand how this innovative treatment affects patients’ lives and treatment side effects compared to older methods.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • no androgen deprivation therapy within the last 2 months prior to RT
• • good performance status (Eastern Cooperative Oncology Group, ECOG, 0/1)
• • no secondary malignancy